The new center will serve as a regional hub where scientists and engineers can work with customers for biological development.
Merck KGaA officially opened its new Life Science Center in Burlington, MA on Oct. 11, 2017 to serve as a regional hub for scientific advancement and collaboration. The new 280,000-ft2 center houses nearly 1000 employees, an M Lab collaboration center, a customer service and call center, and a shared exploratory environment where the company’s scientists and engineers work with customers to learn about the latest techniques in biomanufacturing
In addition, at year-end, the company will also open the region’s first BioReliance End-to-End Biodevelopment Center for small-scale drug manufacturers who are expected to use the lab for early-phase clinical trials. Drug manufacturers will get full support with process development and production as well as regulatory, quality, and training.
The company’s life sciences business operates as MilliporeSigma in the United States and Canada. It acquired Millipore in 2010 and Sigma-Aldrich in 2015. Prior to the latter acquisition, MilliporeSigma was known as EMD Millipore in the US and Canada.
Source: Merck KGaA
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.